количество зарегистрированных пользователей: 68857

Rumedo Медицинский образовательный портал

МЕДИЦИНСКИЙ ОБРАЗОВАТЕЛЬНЫЙ ПОРТАЛ

Академия инновационного образования

БИБЛИОТЕКА

По категориям

По специальностям

  • Зарубежные материалы

    Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study

    Дата публикации 22.10.2020
    Автор: Tina Ken Schramm, Gunnar Hilmar Gislason, Allan Vaag, Jeppe Nørgaard Rasmussen, Fredrik Folke, Morten Lock Hansen, Emil Loldrup Fosbøl, Lars Køber, Mette Lykke Norgaard, Mette Madsen, Peter Riis Hansen, and Christian Torp-Pedersen

    The impact of insulin secretagogues (ISs) on long-term major clinical outcomes in type 2 diabetes remains unclear. We examined mortality and cardiovascular risk associated with all available ISs compared with metformin in a nationwide study.

  • Зарубежные материалы

    High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes

    Дата публикации 22.10.2020
    Автор: L. J. M. Boonman-de Winter & F. H. Rutten & M. J. M. Cramer & M. J. Landman & A. H. Liem & G. E. H. M. Rutten & A. W. Hoes

    Aims/hypothesis The aim of this study was to assess the prevalence of (unknown) heart failure and left ventricular dysfunction in older patients with type 2 diabetes.

  • Зарубежные материалы

    Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientifc evidence from across the world in 2007–2017

    Дата публикации 22.10.2020
    Автор: Thomas R. Einarson, Annabel Acs, Craig Ludwig and Ulrik H. Panton

    Te International Diabetes Federation (IDF) estimates that worldwide, 415 million people have diabetes, 91% of whom have type 2 diabetes mellitus (T2DM). People with diabetes comprise 8.8% of the world’s population, and IDF predicts that the number of cases of diabetes will rise to 642 million by 2040

  • Статьи

    Алгоритмы специализированной медицинской помощи больным сахарным диабетом (9-й выпуск)

    Дата публикации 22.10.2020
    Под редакцией: И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова

    Данное издание содержит восьмой актуализированный выпуск клинических рекомендаций по стандартизации и оптимизации оказания медицинской помощи больным сахарным диабетом во всех регионах России на основе доказательной медицины.

  • Зарубежные материалы

    Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (The new england journal of medicine)

    Дата публикации 22.10.2020
    Автор: Steven P. Marso, M.D., Gilbert H. Daniels, M.D., Kirstine Brown-Frandsen, M.D., Peter Kristensen, M.D., E.M.B.A., Johannes F.E. Mann, M.D., Michael A. Nauck, M.D., Steven E. Nissen, M.D., Stuart Pocock, Ph.D., Neil R. Poulter, F.Med.Sci., Lasse S. Ravn, M.D., Ph.D., William M. Steinberg, M.D., Mette Stockner, M.D., Bernard Zinman, M.D., Richard M. Bergenstal, M.D., and John B. Buse, M.D., Ph.D., for the LEADER Steering Committee on behalf of the LEADER Trial Investigators

    The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.

  • Зарубежные материалы

    Prevalence of Low Glomerular Filtration Rate in Nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III)

    Дата публикации 22.10.2020
    Автор: Department of Medicine, McMaster University, Hamilton, Ontario; Department of Medicine, University of Western Ontario, London, Ontario; Health Research Methodology Graduate Program, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario; and Department of Medicine, Dalhousie University, Halifax, Nova Scotia

    End-stage renal disease is an important and costly health problem. Strategies for its prevention are urgently needed. Knowledge of the population-based prevalence of renal insufficiency in nondiabetic adults would inform such strategies.

  • Зарубежные материалы

    Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

    Дата публикации 22.10.2020
    Автор: Rury R. Holman, F.Med.Sci., M. Angelyn Bethel, M.D., Robert J. Mentz, M.D., Vivian P. Thompson, M.P.H., Yuliya Lokhnygina, Ph.D., John B. Buse, M.D., Ph.D., Juliana C. Chan, M.D., Jasmine Choi, M.S., Stephanie M. Gustavson, Ph.D., Nayyar Iqbal, M.D., Aldo P. Maggioni, M.D., Steven P. Marso, M.D., Peter Öhman, M.D., Ph.D., Neha J. Pagidipati, M.D., M.P.H., Neil Poulter, F.Med.Sci., Ambady Ramachandran, M.D., Bernard Zinman, M.D., and Adrian F. Hernandez, M.D., M.H.S., for the EXSCEL Study Group*

    The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown.

  • Зарубежные материалы

    National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification

    Дата публикации 22.10.2020
    Автор: Andrew S. Levey, MD; Josef Coresh, MD, PhD; Ethan Balk, MD, MPH; Annamaria T. Kausz, MD, MS; Adeera Levin, MD; Michael W. Steffes, MD, PhD; Ronald J. Hogg, MD; Ronald D. Perrone, MD; Joseph Lau, MD; and Garabed Eknoyan, MD

    Chronic kidney disease is a worldwide public health problem with an increasing incidence and prevalence, poor outcomes, and high cost. Outcomes of chronic kidney disease include not only kidney failure but also complications of decreased kidney function and cardiovascular disease.

  • Зарубежные материалы

    Cardiorenal Syndrome

    Дата публикации 22.10.2020
    Автор: Claudio Ronco, MD, Mikko Haapio, MD, Andrew A. House, MSC, MD, Nagesh Anavekar, MD, Rinaldo Bellomo, MD

    The term cardiorenal syndrome (CRS) increasingly has been used without a consistent or well-accepted definition. To include the vast array of interrelated derangements, and to stress the bidirectional nature of heartkidney interactions, we present a new classification of the CRS with 5 subtypes that reflect the pathophysiology, the time-frame, and the nature of concomitant cardiac and renal dysfun ...

  • Зарубежные материалы

    2018 ESC/ESH Guidelines for the management of arterial hypertension

    Дата публикации 22.10.2020
    Автор: Bryan Williams* (ESC Chairperson) (UK), Giuseppe Mancia* (ESH Chairperson) (Italy), Wilko Spiering (The Netherlands), Enrico Agabiti Rosei (Italy), Michel Azizi (France), Michel Burnier (Switzerland), Denis L. Clement (Belgium), Antonio Coca (Spain), Giovanni de Simone (Italy), Anna Dominiczak (UK), Thomas Kahan (Sweden), Felix Mahfoud (Germany), Josep Redon (Spain), Luis Ruilope (Spain), Alberto Zanchetti† (Italy), Mary Kerins (Ireland), Sverre E. Kjeldsen (Norway), Reinhold Kreutz (Germany), Stephane Laurent (France), Gregory Y. H. Lip (UK), Richard McManus (UK), Krzysztof Narkiewicz (Poland), Frank Ruschitzka (Switzerland), Roland E. Schmieder (Germany), Evgeny Shlyakhto (Russia), Costas Tsioufis (Greece), Victor Aboyans (France), and Ileana Desormais (France)

    The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)

  • Статьи

    Артериальная гипертензия у взрослых

    Дата публикации 22.10.2020
    Разработчик клинической рекомендации: Российское кардиологическое общество

    Артериальная гипертензия (АГ) — синдром повышения клинического артериального давления (АД) при гипертонической болезни и симптоматических АГ выше пороговых значений, определенных в результате эпидемиологических и рандомизированных контролируемых исследований, продемонстрировавших связь с повышением сердечнососудистого риска и целесообразность и пользу лечения, направленного на снижение АД ниже ...

  • Зарубежные материалы

    Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

    Дата публикации 22.10.2020
    Автор: Eri T. Kato, MD, MPH, PhD et al

    In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the composite end point of cardiovascular death/hospitalization for heart failure (HHF) in a broad population of patients with type 2 diabetes mellitus. However, the impact of baseline left ventricular ejection fraction (EF) ...

  • Зарубежные материалы

    Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

    Дата публикации 22.10.2020
    Автор: Jennifer B. Green, M.D., M. Angelyn Bethel, M.D., Paul W. Armstrong, M.D., John B. Buse, M.D., Ph.D., Samuel S. Engel, M.D., Jyotsna Garg, M.S., Robert Josse, M.B., B.S., Keith D. Kaufman, M.D., Joerg Koglin, M.D., Scott Korn, M.D., John M. Lachin, Sc.D., Darren K. McGuire, M.D., M.H.Sc., Michael J. Pencina, Ph.D., Eberhard Standl, M.D., Ph.D., Peter P. Stein, M.D., Shailaja Suryawanshi, Ph.D., Frans Van de Werf, M.D., Ph.D., Eric D. Peterson, M.D., M.P.H., and Rury R. Holman, M.B., Ch.B., for the TECOS Study Group*

    Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease.

  • Зарубежные материалы

    Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and theEuropeanAssociation for the Study of Diabetes (EASD)

    Дата публикации 22.10.2020
    Автор: Melanie J. Davies,1,2 David A. D’Alessio,3 Judith Fradkin,4 Walter N. Kernan,5 Chantal Mathieu,6 Geltrude Mingrone,7,8 Peter Rossing,9,10 Apostolos Tsapas,11 Deborah J. Wexler,12,13 and John B. Buse14

    The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education ...

  • Зарубежные материалы

    Eligibility Varies Among the 4 Sodium-Glucose Cotransporter-2 Inhibitor Cardiovascular Outcomes Trials: Implications for the General Type 2 Diabetes US Population

    Дата публикации 22.10.2020
    Автор: Eric T. Wittbrodt, PharmD, MPH; James M. Eudicone, MS, MBA; Kelly F. Bell, PharmD, MSPhr; Devin M. Enhoffer, PharmD; Keith Latham, PharmD; and Jennifer B. Green, MD

    In 2015, more than 23 million adults in the United States had a diagnosis of diabetes, with an estimated 95% of cases being type 2 diabetes (T2D). Patients with T2D are at increased risk of cardiovascular disease (CVD),2 and therefore, improvement of cardiovascular (CV) outcomes is a goal of diabetes management.3,4 Good glycemic control in T2D has been associated with a reduced risk of microvascul ...